HOMA-IR Test

Your fasting blood sugar could look perfectly normal for years while your body quietly compensates by pumping out more and more insulin to keep it that way. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) catches that hidden compensation. It calculates how hard your pancreas is working to maintain normal blood sugar, and a rising score signals that your cells are becoming resistant to insulin long before glucose itself climbs out of range.

This matters because insulin resistance is not just a stepping stone to diabetes. It independently predicts heart disease, fatty liver disease, certain cancers, and earlier death, even in people whose blood sugar never crosses a diagnostic threshold. If you want to know whether your metabolism is quietly drifting in the wrong direction, this is one of the most direct ways to find out.

How the Score Is Calculated

HOMA-IR is not something your body produces. It is a mathematical index calculated from two fasting blood measurements: insulin and glucose. The formula is simple: multiply your fasting insulin (in µIU/mL) by your fasting glucose (in mg/dL), then divide by 405. A higher score means your body needs more insulin to keep blood sugar in check, which is the hallmark of insulin resistance.

The score primarily reflects what is happening in your liver. Under fasting conditions, your liver is the main organ responsible for releasing glucose into the bloodstream, and insulin's job is to keep that release in check. When your liver becomes less responsive to insulin, both fasting glucose and fasting insulin rise, and so does your HOMA-IR. In people with elevated fasting glucose, liver insulin sensitivity accounts for about 40% of HOMA-IR's variation. The score also captures, to a lesser degree, how well your muscles and other tissues take up glucose.

Heart Disease Risk

Insulin resistance is one of the strongest metabolic drivers of cardiovascular disease, and HOMA-IR captures this risk with striking consistency across populations. A meta-analysis pooling data from over 516,000 participants across 65 studies found that people in the highest HOMA-IR category were about 64% more likely to develop coronary heart disease than those in the lowest category. For each standard deviation increase in HOMA-IR, the risk rose by 46%, a stronger signal than either fasting glucose or fasting insulin provided on its own.

The Bruneck Study, which followed 919 adults for 15 years, found that people in the top quarter of HOMA-IR were about 2.2 times as likely to develop symptomatic cardiovascular disease. That association barely budged after adjusting for blood pressure, LDL cholesterol, HbA1c, BMI, triglycerides, inflammatory markers, and other risk factors, suggesting that insulin resistance contributes to heart disease through pathways not fully captured by standard risk markers.

Perhaps most telling is what happens when HOMA-IR trends upward over time. A Korean cohort study tracking over 6,700 adults found that those whose HOMA-IR increased over a six-year exposure period (compared to those whose score stayed stable) had 59% higher risk of cardiovascular events, 87% higher risk of dying from any cause, and nearly four times the risk of dying from a major cardiovascular event. The trajectory of insulin resistance matters as much as any single reading.

Type 2 Diabetes

HOMA-IR's most intuitive application is spotting the metabolic drift toward diabetes years before it arrives. In a large Chinese cohort, HOMA-IR above 3.45 was the threshold most strongly associated with type 2 diabetes. A 15-year prospective study in Hong Kong identified progressively meaningful cutpoints: a HOMA-IR of 1.4 (the 75th percentile of persistently healthy individuals) marked the onset of early blood sugar irregularities, while 2.0 (the 90th percentile) flagged meaningful diabetes risk.

The relationship between insulin resistance and cardiovascular risk also depends on where you stand on the glucose spectrum. In the China Cardiometabolic Disease and Cancer Cohort of more than 111,000 adults, the cardiovascular impact of high HOMA-IR grew stronger as glucose tolerance worsened. Among people with normal glucose, the top quarter of HOMA-IR had no significant increase in heart disease risk. But among those with prediabetes, the top quarter had 23% higher risk, and among those with diabetes, 61% higher risk. Insulin resistance and glucose dysregulation amplify each other.

Cancer and Mortality

The Women's Health Initiative followed nearly 23,000 postmenopausal women for close to 19 years and found that women in the highest quarter of HOMA-IR were 63% more likely to die from any cause and 26% more likely to die specifically from cancer compared to women in the lowest quarter. A separate analysis from the same cohort found that high HOMA-IR was associated with 34% higher breast cancer incidence and 78% higher risk of dying after a breast cancer diagnosis.

A meta-analysis of nearly 27,000 non-diabetic adults confirmed that higher HOMA-IR independently predicted death from cardiovascular causes, with over twice the risk in the highest category compared to the lowest. Fasting insulin alone did not show the same predictive power, suggesting that the combination of insulin and glucose captured by HOMA-IR provides information that neither measurement offers in isolation.

Fatty Liver Disease

Insulin resistance and fatty liver disease are tightly linked: the liver is both a target and a driver of metabolic dysfunction. A HOMA-IR cutoff of 1.9 identified fatty liver (defined as liver fat above 5.56%) with 87% sensitivity and 79% specificity in a Finnish population study. In patients who already have fatty liver disease without diabetes, HOMA-IR independently predicts which ones will develop advanced scarring. Each one-unit increase in HOMA-IR was associated with a 16% higher likelihood of significant liver fibrosis, and baseline HOMA-IR predicted fibrosis progression over an eight-year follow-up.

Kidney Function

Insulin resistance also takes a toll on the kidneys. A Korean cohort of over 5,300 adults without chronic kidney disease found that those whose HOMA-IR increased over time were about twice as likely to develop kidney problems compared to those whose levels stayed stable. A separate 18-year follow-up study showed similar patterns, with increasing HOMA-IR trajectories predicting reduced kidney function in both men and women.

Reference Ranges

There is no single universally agreed-upon cutoff for HOMA-IR, and values vary by ethnicity, lab, and the insulin assay used. The same blood sample can yield a HOMA-IR of 1.3 in one lab and 2.1 in another because insulin assays vary by about 25% between laboratories. That said, a large body of population research provides useful orientation.

These tiers are drawn from published research across multiple populations. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend. Chinese populations tend to have lower thresholds (1.4 for early glucose irregularities), while some Western studies use 2.5 as the general cutoff. The Gutenberg Health Study in Germany found a median of 1.09 in a healthy reference group, with the 97.5th percentile at 2.35.

One nuance worth knowing: NHANES mortality data revealed a J-shaped relationship between insulin resistance scores and death risk. Both very low and very high values were associated with increased mortality, with inflection points around 1.75 to 1.85 in individuals with obesity. This does not mean low insulin resistance is dangerous, but it does suggest that extremely low scores in certain populations may reflect other health issues worth investigating.

Tracking Your Trend

A single HOMA-IR reading is a starting point, not a verdict. The within-person variability of this score is about 23 to 30%, meaning your result on any given day can swing meaningfully due to biological fluctuation alone. In people with type 2 diabetes, the variability is even greater: a follow-up measurement must increase by more than 90% or decrease by more than 47% to be considered a statistically meaningful change from baseline.

That sounds discouraging, but the trajectory research tells a different story. Studies that track HOMA-IR over years consistently find that the direction of your trend predicts outcomes far better than any single number. People whose HOMA-IR drifts upward over time face dramatically higher cardiovascular and kidney disease risk. People who bring their score down through weight loss, exercise, or other interventions see measurable reductions in metabolic risk. The pattern over time is the signal; any single reading is just noise.

Get a baseline, and if you are making dietary, exercise, or medication changes aimed at improving insulin sensitivity, retest in 3 to 6 months. After that, test at least annually. Always use the same lab to minimize the impact of assay variation on your trend.

When Results Can Be Misleading

HOMA-IR requires a proper overnight fast of at least 8 to 10 hours. Eating before the blood draw invalidates the result entirely, because the formula assumes steady-state fasting conditions. Even the timing of your fast matters: altered meal schedules can paradoxically shift insulin and glucose levels in ways that distort the score.

Acute illness is the most common cause of a misleadingly high HOMA-IR. Infections trigger a surge in insulin resistance that can persist for one to three months after recovery, producing temporary spikes comparable to the levels seen in severely obese or elderly individuals. If you have been sick in the past month, consider waiting before testing. Surgery has a similar effect, causing a 42 to 45% reduction in insulin sensitivity that HOMA-IR may not fully capture (gold-standard methods detect much larger changes than HOMA-IR does in surgical settings).

Intense exercise within 24 to 48 hours of a blood draw can temporarily improve insulin sensitivity and lower your HOMA-IR, making your result look better than your baseline. For the most representative reading, avoid unusually strenuous workouts the day before testing.

Several commonly prescribed medications shift HOMA-IR without necessarily reflecting a true change in your metabolic health. Statins increase HOMA-IR modestly (by about 0.3 to 0.5 units on average), likely through mechanisms unrelated to the metabolic dysfunction the score is designed to detect. Corticosteroids produce larger increases (33 to 47%), driven by both liver and muscle effects on glucose handling. If you take either medication, your HOMA-IR will run higher than your underlying insulin sensitivity would suggest. GLP-1 receptor agonists and metformin lower HOMA-IR as part of their therapeutic mechanism, which does reflect genuine improvement in insulin sensitivity.

Kidney function also affects interpretation. In people with moderate to advanced chronic kidney disease (eGFR around 30 mL/min), insulin sensitivity is low regardless of body weight, and the usual relationship between BMI and HOMA-IR breaks down. If your kidney function is impaired, discuss HOMA-IR interpretation with your physician.